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ABSTRACT
Previously we have demonstrated that striated muscle GLUT4
gene expression decreased following streptozotocin-induced diabetes
due to a loss of MEF2A transcription factor expression without any
significant effect on the MEF2D isoform (Mora, S. and J. E. Pessin
(2000) J Biol Chem, 275:16323–16328). In contrast to both cardiac and
skeletal muscle, adipose tissue displays a selective decrease in
MEF2D expression in diabetes without any significant alteration in
MEF2A protein content. Adipose tissue also expresses very low levels
of the MEF2 transcription factors and nuclear extracts from white
adipose tissue exhibit poor in vitro binding to the MEF2 element.
However, addition of in vitro synthesized MEF2A to adipose nuclear
extracts results in the formation of the expected MEF2/DNA complex.
More importantly, binding to the MEF2 element was also compro-
mised in the diabetic condition. Furthermore, in vivo overexpression
of MEF2A selectively in adipose tissue did not affect GLUT4 or
MEF2D expression and was not sufficient to prevent GLUT4 down-
regulation that occurred in insulin-deficient states. (Endocrinology
142: 1999–2004, 2001)
THE GLUT4 facilitative glucose transporter is the majorinsulin-responsive glucose transporter and is predom-
inantly expressed in adipose and striated muscle tissues (1–
3). In the basal state, this transporter slowly recycles between
a poorly described intracellular compartment and the plasma
membrane such that in the steady-state this carrier is local-
ized mainly inside the cell (3–7). Upon insulin stimulation,
this transporter redistributes to the plasma membrane,
thereby increasing the number of functional glucose trans-
porters at the cell surface and enhancing glucose uptake (1,
3, 5, 6, 8–10).
In addition to this acute regulation of GLUT4 subcellular
localization, the expression of the GLUT4 gene is also under
dynamic regulatory control. In insulin-deficient states such
as fasting or streptozotocin [STZ (1)]-induced diabetes, both
GLUT4 messenger RNA and protein content are severely
down-regulated in adipose, cardiac, and skeletal muscle (11–
16). Although the loss of GLUT4 protein expression can occur
at multiple levels, there is a near complete transcriptional
inhibition in STZ-induced diabetes (17).
Promoter studies performed in both tissue culture cell
lines and in transgenic mice have revealed the presence of
two critical cis-DNA elements in the transcriptional control
of this gene. Oshel et al. (18) have identified a regulatory
element (Domain I) located between 2712 and 2772 of the
human GLUT4 promoter that binds a 70-kDa protein. Other
studies have also identified a MEF2 binding element located
between 2473 and 2464 (19). Mutational analysis of the
MEF2 element has demonstrated its functional necessity for
tissue-specific and hormonal/metabolic regulation (20, 21).
More recently, we have demonstrated that cardiac and skel-
etal muscle expression of GLUT4 is dependent upon the
binding of a MEF2A-MEF2D heterodimer complex to this
element (22). STZ-induced insulin deficiency resulted in a
specific decrease in MEF2A protein content in striated mus-
cle, which in turn resulted in a decreased binding to the
MEF2 element (22). These data demonstrated that the
MEF2A isoform was a critical factor in muscle-specific reg-
ulation of GLUT4 gene expression.
In our continuous efforts to analyze the functional role
of MEF2 in GLUT4 transcriptional regulation, we have
now observed that in contrast to striated muscle, STZ-
induced diabetes resulted in a selective loss of MEF2D
expression in adipose tissue without any significant effect
on the MEF2A isoform. Furthermore, overexpression of
MEF2A in adipose tissue was not sufficient to prevent
GLUT4 down-regulation.
Materials and Methods
Generation of transgenic mice
Human MEF2A full complementary DNA was cloned into the MluI
and NotI sites of pSTEC vector (obtained from Dr. Curt Sigmund, The
University of Iowa) and the AP2 promoter (kindly provided by Dr.
Barbara Kahn, Harvard Medical School) was cloned upstream into the
HindIII and SphI sites. Constructs were then linearized, purified, and
injected into the male pro-nucleus followed by implantation into a
pseudopregnant female mice. Positive founders were identified by
PCR and Southern blot analysis. All procedures were reviewed and
approved by the University of Iowa Committee for the Care and Use
of Animals.
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Animal maintenance
Animals were housed in 12-h light, 12-h dark cycle and fed ad libitum.
Experimental diabetes was performed by a single ip injection of STZ, 200
mg/kg for mice and 85–100 mg/kg for rats. Following 3–4 days after the
STZ injection, blood tail samples were analyzed for glucose concentra-
tion using a One Touch glucometer (Lifescan, Milpitas, CA). Mice with
glycemia higher than 400 mg/dl and rats with glycemia higher than 300
mg/dl were considered diabetic. Three to five days following the STZ
injection, animals were killed by CO2 asphyxiation. One set of diabetic
rats were subsequently treated with insulin for 7 days as previously
described (22).
Preparation of tissue extracts and Western blotting
Adipose tissue from individual mice was carefully minced in a buffer
containing 30 mm Tris, pH 7.4, 100 mm NaCl, 1 mm EDTA, 1% Triton
X-100, 50 mm NaF, 2 mm sodium pyrophosphate, 1 mm sodium vana-
date, 1 mm phenylmethylsulfonyl fluoride (PMSF), 2 mg/ml aprotinin, 2
mg/ml pepstatin A, and 2 mg/ml leupeptin. Samples were subsequently
homogenized with 20 strokes in a Dounce homogenizer in ice and incu-
bated for 15 min at 17 C. Samples were then centrifuged at 13,000 3 g for
10 min at 4 C to remove insoluble materials. Protein content in the super-
natants was assayed by the BCA method (Pierce Chemical Co., Rockford,
IL). Samples were then run in an SDS-PAGE and transferred onto a nitro-
cellulose filter and subsequently immunoblotted with various antibodies as
indicated in the individual figure legends.
Nuclear extracts from adipocytes
Epididymal fat pads from four to five Sprague Dawley rats were
pooled together, minced, and digested with type I collagenase (Harlan,
Inc., Indianapolis, IN) (Worthington Biochemical Corp., Lakewood, NJ)
in a Krebs-Ringer-HEPES (KRHB) buffer (30 mm HEPES, pH 7.4, 120 mm
NaCl, 4 mm KH2PO4, 1 mm MgSO4, 75 mm CaCl2, 10 mm NaHCO3, 1%
BSA), for 45 min to 1 h at 37 C with gentle agitation. After digestion,
adipocytes were filtered through a cotton mesh and washed 4 times with
KRHB buffer and twice quickly in hypotonic buffer (10 mm HEPES, pH
7.6, 1.5 mm MgCl2, 10 mm KCl, 0.5 mm DTT, 0.2 mm PMSF, 2 mg/ml each
aprotinin, pepstatin A, leupeptin, and 6 mg/ml each TPCK and TLCK).
After the last wash, cells were incubated at room temperature for 10 min
in 10 ml of this buffer and subsequently homogenized in the same buffer
using a glass Dounce homogenizer on ice. Nuclei were pelleted by cen-
trifugation at 3,000 3 g for 20 min at 4 C. To obtain a crude total membrane
preparation, the supernatant was centrifugated at 200,000 3 g for 90 min.
Nuclear protein extracts were obtained by incubating the isolated
nuclei in one volume of nuclear extraction buffer (10 mm HEPES, pH 7.6,
400 mm KCl, 3 mm MgCl2, 0.1 mm EDTA, 10% glycerol, 1 mm dithio-
threitol) supplemented with 1/10 of a volume of 4 m KCl (;725 mm KCl
final), and the extraction was allowed to proceed for 30 min at 4 C. After
extraction, the insoluble nuclei were precipitated by centrifugation at
13,000 3 g for 15 min. The nuclear extract was then dialyzed against a
buffer containing 25 mm HEPES, pH 7.5, 100 mm KCl, 0.1 mm EDTA, 10%
glycerol, 1 mm DTT, 0.1 mm PMSF, 2 mg/ml each of pepstatin, aprotinin,
leupeptin, and 6 mg/ml each of TLCK and TPCK for 2–3 h at 4 C. The
extracts were quantified for protein content using the BCA method
(Pierce Chemical Co.) and frozen in small aliquots at 270 C.
Electrophoretic mobility shift assay (EMSA)
EMSA analysis was performed as previously described using oligo-
nucleotides carrying the MEF2 element (22). Control EMSA using a
PPAR specific oligonucleotide was performed using a Gelshift kit from
Geneka Biotechnology (Montréal, Canada).
Results
Previously, we determined that the MEF2A-MEF2D het-
erodimer is the primary complex that binds to the GLUT4
MEF2 cis-DNA element CTAAAAATAG (22). In these stud-
ies, insulin-deficient diabetes was found to specifically result
in a loss of MEF2A protein in striated muscle. To compare the
expression pattern of MEF2A and MEF2D in adipose tissue,
Western blots were performed on nuclear protein extracts
isolated from cardiac muscle and adipose tissue (Fig. 1). As
previously reported, STZ-induced diabetes resulted in a de-
crease in cardiac GLUT4 protein levels, which recovered
following insulin therapy. In parallel with the loss of GLUT4
protein, the MEF2A isoform also declined in STZ-diabetes
and recovered following insulin treatment. However,
MEF2D protein expression levels were unaffected. The
changes in MEF2A in the heart were in marked contrast to
that in adipose tissue. Even though STZ-diabetes resulted in
a marked decrease in GLUT4 protein, there was essentially
no change in the expression levels of MEF2A. Instead, STZ-
diabetes resulted in a dramatic decline in the protein levels
of MEF2D, which fully recovered following insulin treat-
ment. It is important to note that the relative levels of MEF2A
and MEF2D between tissues cannot be inferred from these
immunoblots as longer exposure times were required to
visualize these bands in the adipose tissue extracts.
To determine whether the loss of MEF2D expression had
any effect on the binding to the MEF2 site, we next performed
EMSA on heart and adipose tissue nuclear extracts (Fig. 2A).
As expected, a specific MEF2 binding complex was detected
FIG. 1. MEF2A and MEF2D expres-
sion are differentially regulated in car-
diac muscle and white adipose tissue.
Nuclear extracts were obtained from ei-
ther the heart or epididymal white ad-
ipose tissue of control (C), STZ-induced
diabetic (D), or insulin-treated diabetic
(I) rats as described in Materials and
Methods. The extracts (30–50 mg) were
then subjected to Western blotting us-
ing MEF2A or MEF2D specific antibod-
ies. Total cell membrane preparations
were immunoblotted for GLUT4. These
are representative blots from two inde-
pendent experiments. The exposure
times for the adipose tissue extracts
were approximately four times longer
than that for the heart extracts.
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in heart nuclear extracts and was specifically competed by
excess of unlabeled MEF2 oligonucleotide. Surprisingly
however, we were unable to detect any specific MEF2 bind-
ing complex in control, diabetic or insulin-treated diabetic
nuclear extracts from adipose tissue. This was not due to the
preparation of nonfunctional adipose tissue nuclear extracts
as they were fully capable of displaying specific binding to
a control PPAR cis-DNA element with the three bands de-
tected corresponding to the three different PPAR (a,b,g)
isoforms (Fig. 2B). These data suggest that the level of the
MEF2A-MEF2D heterodimeric protein expression in adipose
tissue nuclear extracts is either too low to be detected in this
assay or alternatively, the endogenous MEF2 transcription
factors are repressed in the adipose tissue extracts, thereby
preventing their binding to this element.
If the relative functional levels of MEF2 were too low to be
detected by these assay, then the addition of in vitro trans-
lated MEF2A should restore binding to the MEF2 element. As
can be seen in Fig. 3A, a specific MEF2 binding complex was
detected in heart nuclear extracts but was not present in the
adipose tissue nuclear extracts. Addition of in vitro translated
MEF2A to the adipose tissue nuclear extracts resulted in the
appearance of specific MEF2 binding complexes. One of
these bands matched with the mobility of the MEF2A-
MEF2D heterodimer band observed in heart (Fig. 3A) and
was competed upon the addition of cold oligonucleotide
(Fig. 4). In addition, reduced binding activity was observed
in the adipose tissue extracts from diabetic animals com-
pared with the control or following insulin treatment (Fig.
3A). Moreover when in vitro synthesized MEF2D protein was
added to the control or diabetic adipose nuclear extracts, we
could not detect the band matching the mobility of the
MEF2A-MEF2D heterodimer (Fig. 3B). Instead, a band of
higher mobility was observed that was competed with the
addition of cold oligonucleotide. Furthermore, the apparent
mobility of the in vitro synthesized MEF2D homodimer was
less than the MEF2A homodimer but greater than that ob-
served upon the addition of MEF2D to the adipocyte extracts
(Fig. 4). These data indicate that in the absence of MEF2A,
MEF2D can either homodimerize as a nonfunctional complex
and/or also interacts with other factors.
In any case, if MEF2A was potentially a limiting factor then
overexpression of this isoform might be expected to induce
the expression of GLUT4. Thus, to further examine the phys-
iologic role of the MEF2A isoforms in the in vivo expression
of the GLUT4 gene, we used the AP2 promoter to drive the
adipose tissue specific expression of the MEF2A protein (Fig.
5A). The increased expression of MEF2A protein was ob-
served in two independently isolated transgenic lines. In
both cases, however, the increased expression of MEF2A had
no significant effect on the expression of GLUT4 as assessed
by Western blot analysis (Fig. 5A). As typically observed,
STZ-induced diabetes reduced GLUT4 protein levels in ad-
ipose tissue. The insulin-responsive aminopeptidase (IRAP)
is known to colocalize with GLUT4 and undergoes an iden-
tical pattern of insulin-stimulated translocation to the plasma
FIG. 2. White adipose tissue nuclear extracts have very low MEF2 binding activity. A, Nuclear extracts (10 mg) obtained from white adipose
tissue isolated from control (C), diabetic (D), or insulin-treated diabetic animals (I) were incubated with 32P-labeled MEF2 consensus oligo-
nucleotide and subjected to gel electrophoresis as described in Materials and Methods. Ten micrograms of nuclear extracts isolated from heart
were used as a positive control. For competition studies the extracts were incubated with 40-fold of the unlabeled oligonucleotide. B, Nuclear
extracts (5 mg) obtained from white adipose tissue isolated from control (C), diabetic (D) or insulin-treated diabetic animals (I) were incubated
with 32P-labeled PPAR consensus oligonucleotide and subjected to gel electrophoresis as described in Materials and Methods. For competition
studies the extracts were incubated with 100-fold of the unlabeled oligonucleotide.
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membrane (23–26). Interestingly, in contrast to the loss of
GLUT4 protein expression in STZ-diabetes, there was no
significant change in IRAP protein levels. Importantly, the
increase in MEF2A expression did not prevent the decline in
GLUT4 protein levels. Furthermore, increased expression of
MEF2A did not affect the expression of the MEF2D protein
or its decline in STZ-induced diabetes (Fig. 5B). Similarly,
insulin deficiency induced by fasting also resulted in a
marked decrease in adipose tissue GLUT4 expression with
little effect on IRAP expression levels (Fig. 6). Although fast-
ing had no effect on MEF2A protein levels, there was a
significant reduction in the expression of MEF2D. Similar to
STZ-induced diabetes, increased MEF2A expression did not
prevent the fasting-dependent decline in either GLUT4 or
MEF2D protein levels.
Discussion
It is well established that one of the major acute actions of
insulin is the recruitment of the GLUT4 glucose transporter
protein from intracellular storage sites to the plasma mem-
brane in striated muscle and adipose tissue (1, 2, 8, 27, 28).
However, in addition to this acute action of insulin, the
expression levels of GLUT4 messenger RNA and protein are
also regulated by a variety of more chronic hormonal/nu-
tritional/metabolic states. For example, GLUT4 expression is
markedly up-regulated during muscle and adipose differ-
entiation and following muscle exercise/contraction (29–31).
In contrast, states of insulin deficiency such as Type I diabetes
or fasting result in decreased GLUT4 expression due to tran-
scriptional repression (12, 15–17, 32).
Recent promoter analyses have identified two potential
cis-DNA sequence elements in the GLUT4 promoter that are
necessary for both tissue-specific and hormonal/metabolic
regulation (18–20). The specific binding of the MEF2 tran-
scription factor to the GLUT4 consensus MEF2 binding site
(2473/2464) is down-regulated in STZ-induced insulin de-
ficiency but is fully restored following insulin treatment (21,
22). Although there are four MEF2 isoforms, this site appears
to interact with a heterodimeric complex composed of the
MEF2A-MEF2D isoforms (22). In addition, insulin deficiency
appears to result in a selective decrease in MEF2A expression
in both cardiac and skeletal muscle (22). In the present study,
we have recapitulated this finding that insulin deficiency results
in a selective loss of the MEF2A isoform in striated muscle.
However, white adipose tissue displays a markedly different
pattern of MEF2 isoform regulation. In this tissue, STZ-induced
diabetes results in a selective decrease in MEF2D expression
without any significant alteration in MEF2A expression.
FIG. 3. Addition of MEF2A to white adipose nuclear extracts restores MEF2 binding activity. A, Nuclear extracts (20 mg) obtained from white
adipose tissue isolated from control (C), diabetic (D), and insulin-treated diabetic (I) rats were preincubated with (Adipose 1 MEF2A) or without
(Adipose) in vitro synthesised MEF2A (0.2 ml of reaction) and subsequently with 32P-labeled MEF2 consensus oligonucleotide and subjected
to gel electrophoresis as described in Materials and Methods. Ten micrograms of nuclear extracts isolated from heart were used as a positive
control. B, Nuclear extracts from adipose tissue isolated from control (C) and diabetic (D) mice were preincubated with 0.2 ml of in vitro
synthetised MEF2D (Adipose 1 MEF2D). Extracts were subsequently incubated with 32P-labeled MEF2 consensus oligonucleotide and subjected
to gel electrophoresis as described in Materials and Methods. Ten micgrams of nuclear extracts isolated from heart were used as a positive control.
For competition studies the extracts were incubated with 40-fold of the unlabeled oligonucleotide.
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In either case, the net outcome in both diabetic muscle and
adipose tissue would be the same, rendering a low content
of the MEF2A-MEF2D heterodimer. Surprisingly however,
adipose tissue nuclear extracts exhibited very poor binding
to the MEF2 element, suggesting that either the levels of the
MEF2A-MEF2D heterodimer are extremely low and/or the
DNA binding activity was repressed. Nevertheless, addition
of MEF2A to these extracts restored DNA binding and dem-
onstrated a decreased binding activity in adipose tissue ex-
tracts from diabetic animals. In contrast, addition of in vitro
synthesized MEF2D to either control or diabetic nuclear ex-
tracts did not result in the formation of the MEF2A-MEF2D
heterodimer but instead generated a complex with a slower
mobility. This band more likely corresponded to an het-
erodimer composed of MEF2D with an unidentified protein,
as the mobility seen in several gels appears to be different
from the MEF2D homodimer. These data are consistent with
a low level of MEF2A protein in adipose tissue compared
with striated muscle and is probably rate limiting for the
formation of the MEF2A-MEF2D complex in this tissue. In
this context, down-regulation of MEF2D content by diabe-
tes/fasting would further compromise the formation of the
MEF2A-MEF2D complex. At present, the molecular mech-
anism(s) responsible for this apparent tissue-specific isoform
regulation remains unknown as the elements controlling
MEF2 gene expression have not been determined. Several
studies have reported that phosphorylation by p38 mitogen-
activated protein kinase, the Big mitogen-activated protein
(MAP) kinase (BMK1), calmodulin-dependent protein ki-
nase (CaMK) and PI3-kinase can transcriptionally activate
both MEF2A and MEF2C isoforms (33–37). In addition,
MEF2 can interact with histone deacetylases 4 and 5, result-
ing in the repression of the transcriptional activity of MEF2.
CaMK kinase appears to induce the dissociation of MEF2
from these histone deacetylases, thereby relieving the tran-
scriptional inhibition (38, 39). Further studies will be neces-
sary to determine whether any of these mechanisms are
responsible for the regulation of binding and transcriptional
activation of the MEF2A-MEF2D heterodimer.
In summary, our data demonstrate that the MEF2A and
MEF2D isoforms undergo differential regulation in white
adipose tissue and striated muscle in vivo. The loss of MEF2D
expression in adipose tissue cannot be compensated for by
increased expression of MEF2A. Future studies will be nec-
essary to determine whether forced MEF2D expression can
directly compensate and maintain GLUT4 gene expression in
adipose tissue of insulin-deficient diabetic mice.
FIG. 4. MEF2A but not MEF2D is rate limiting in adipose tissue from
control animals to form a MEF2A-MEF2D complex. Nuclear extracts
from adipose tissue isolated from control animals were preincubated
with either 0.2 ml of in vitro synthesized MEF2A (Adipose 1 MEF2A)
or MEF2D (Adipose 1 MEF2D) and compared with the mobility of in
vitro synthesized MEF2A alone (MEF2A) or MEF2D alone (MEF2D).
Extracts were subsequently incubated with 32P-labeled MEF2 con-
sensus oligonucleotide and subjected to gel electrophoresis as de-
scribed in Materials and Methods. For competition studies the ex-
tracts were incubated with 40-fold of the unlabeled oligonucleotide.
FIG. 5. MEF2A overexpression does not prevent GLUT4 down-
regulation in STZ-induced diabetes. Transgenic mice with adipose
tissue-specific MEF2A expression were prepared as described in Ma-
terials and Methods. Wild-type and transgenic mice were either left
untreated (Control) or made diabetic by STZ treatment (Diabetic).
Whole tissue extracts were then prepared from white adipose tissue
and 10–50 mg of protein subjected to Western blotting with specific
antibodies directed against GLUT4, IRAP, MEF2A, and MEF2D.
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FIG. 6. MEF2A overexpression does not prevent GLUT4 down-
regulation during fasting. Transgenic mice with adipose tissue-
specific MEF2A expression were prepared as described in Materials
and Methods. Wild-type and transgenic mice were either left un-
treated (FED) or fasted for 48 h (FASTED). Whole tissue extracts were
then prepared from white adipose tissue and 10–50 mg of protein was
subjected to Western blotting with specific antibodies directed against
GLUT4, IRAP, MEF2A, and MEF2D.
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